Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings The Wall Street Journal Vertex next-generation pain candidate fails Phase 2 trial statnews.com Vertex shares plummet 15% as next-gen painkiller misses target The Business Journals Vertex drops aspiring Journavx follower in acute pain after phase 2 failure Fierce Biotech Vertex’s pain portfolio is pummeled with setbacks FirstWord Pharma Source link
Read More »